Posted by Michael Wonder on 30 Nov 2020
Forxiga approved in Japan for chronic heart failure
30 November 2020 - Forxiga is the first SGLT2 inhibitor approved in Japan for chronic heart failure with reduced ejection fraction in adult patients with and without type 2 diabetes mellitus.
AstraZeneca’s Forxiga (dapagliflozin) has been approved in Japan for the treatment of patients with chronic heart failure who are receiving standard of care.
